0001421642-22-000003.txt : 20220927 0001421642-22-000003.hdr.sgml : 20220927 20220927113410 ACCESSION NUMBER: 0001421642-22-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220927 DATE AS OF CHANGE: 20220927 EFFECTIVENESS DATE: 20220927 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Satellos Bioscience Inc. CENTRAL INDEX KEY: 0001421642 IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-459948 FILM NUMBER: 221268369 BUSINESS ADDRESS: STREET 1: 65 FRONT STREET EAST STREET 2: SUITE 201 CITY: TORONTO STATE: A6 ZIP: M5E 1B5 BUSINESS PHONE: 905-336-6128 MAIL ADDRESS: STREET 1: 65 FRONT STREET EAST STREET 2: SUITE 201 CITY: TORONTO STATE: A6 ZIP: M5E 1B5 FORMER COMPANY: FORMER CONFORMED NAME: ICO THERAPEUTICS INC DATE OF NAME CHANGE: 20071218 D 1 primary_doc.xml X0708 D LIVE 0001421642 Satellos Bioscience Inc. 65 FRONT STREET EAST SUITE 201 TORONTO A6 ONTARIO, CANADA M5E 1B5 905-336-6128 CANADA (FEDERAL LEVEL) ICO THERAPEUTICS INC Corporation true 2021 Frank Gleeson 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Executive Officer Director Promoter Michael Rudnicki 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Executive Officer Promoter Warren Whitehead 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Executive Officer Geoff MacKay 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Director Adam Mostafa 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Director Brian Bloom 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Director William McVicar 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Director Bill Jarosz 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Director Rima Al-awar 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Director J. Robert Hall 65 Front Street East Suite 201 Toronto A6 ONTARIO, CANADA M5E 1B5 Executive Officer Biotechnology No Revenues 06b false 2022-09-13 true true true true true Each unit consists of one common share and one-half of one common share purchase warrant. Each warrant is exercisable for one common share at an exercise price of $.60 until September 13, 2025 false 0 2101450 99161 2002289 The additional $2,002,289 may be received upon the exercise of purchase warrants sold inside or outside the U.S. The U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on September 13, 2022, which was Cdn$1.3110=USD$1.00 false 1 0 0 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false Satellos Bioscience Inc. Frank Gleeson Frank Gleeson President and Chief Executive Officer 2022-09-26